Information contained on this page is provided by an independent third-party content provider. WorldNow and this Station make no warranties or representations in connection therewith. If you have any questions or comments about this page please contact email@example.com.
SOURCE LabStyle Innovations Corp.
Commercial roll-out of Dario™ expected to continue in 2014 with the soft launch of the Dario™ software and the 'all-in-one', pocket-sized, Dario™ blood glucose monitoring device, in select markets
RAMAT GAN, Israel, Dec. 12, 2013 /PRNewswire/ -- LabStyle Innovations Corp. (OTCQB: DRIO), developer of Dario™, a cloud-based, mobile health (mHealth) platform for diabetes and related blood glucose monitoring, announced that the world roll-out of the Dario™ diabetes management platform is now in progress with today's market launch of the Dario™ iOS app in the United Kingdom, New Zealand and Australia.
Customers in these countries are invited to download the complimentary app from the Apple App Store. The app works with all blood glucose monitoring devices. By simply manually inputting blood glucose information, customers will be able to experience the novel functionality and benefits of Dario™'s iOS app.
"With the introduction of the Dario™ iOS app, we officially begin the world roll-out of the complete Dario™ diabetes management platform. Customers can now easily and instantly check blood sugar levels using their smartphone and gain useful insights and views regarding the management of their condition. Starting today, diabetes management just got easier, social and much more enjoyable," said LabStyle's president and chief executive officer Erez Raphael.
Mr. Raphael continued, "Based on the feedback from various focus groups conducted in the last few months, in London, San Antonio and other locations, we believe the Dario™ iOS app will be well received within the diabetes community. In our field testing, those who have already sampled the Dario™ iOS app report its features to be insightful, efficient, helpful and even fun. We are thrilled that this experience is now available to the public, and just in time for holiday festivities. Seasons greetings from all of us at LabStyle Innovations. We are wishing everyone happy, healthy and safe celebrations."
"The complete Dario™ platform is designed to capture the full diabetic landscape from monitoring to therapy. We also believe Dario™ is the only end-to-end mobile health platform that encourages compliance by offering people living with diabetes a new way to understand and control their condition," said LabStyle executive chairman and co-founder Dr. Oren Fuerst. "We are all extremely excited about today's launch and achieving this important milestone in just 28 months since our founding. We very much look forward to continuing the world roll-out of the complete Dario platform throughout 2014 in Europe and selected areas in the Asia-Pacific region and, assuming regulatory approval, later in 2014, in the U.S."
The Dario™ diabetes management platform includes the novel Dario™ app (currently available for iOS and to be available in 2014 for Android), website software, and a stylish, 'all-in-one', pocket-sized, Dario™ blood glucose monitoring device, which comes complete with lancet, strips and a glucose meter. The glucose meter connects to a smartphone and the feature rich Dario™ mobile and website applications enabling patients, medical professionals and caregivers to access and analyze data in real time.
LabStyle remains on course to launch the Dario™ iOS app in Italy and Belgium and the Dario Android app, in the United Kingdom, New Zealand, Australia, Italy and Belgium – both during first quarter 2014. Plans are also on track to soft launch the Dario™ all-in-one blood glucose monitoring device in the United Kingdom, Italy, Belgium, New Zealand and Australia during first quarter 2014.
About LabStyle Innovations
LabStyle Innovations Corp. (OTCQB: DRIO) is a mobile health (mHealth) company developing and commercializing patent-pending technology providing consumers with laboratory-testing capabilities using smart phones. LabStyle's flagship product, Dario™, is a mobile, cloud-based, diabetes management platform which includes a stylish, 'all-in-one', pocket-sized, blood glucose monitoring device, iOS and Android apps and a web application. Dario™ received CE mark certification in September 2013 and is pursuing patent applications in multiple jurisdictions covering the specific processes related to blood glucose level measurement as well as more general methods of rapid tests of body fluids using mobile devices and cloud-based services. For more information: www.mydario.com.
Cautionary Note Regarding Forward-Looking Statements
This news release and the statements of representatives and partners of LabStyle Innovations Corp. (the "Company") related thereto contains or may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Statements that are not statements of historical fact may be deemed to be forward-looking statements. Without limiting the generality of the foregoing, words such as "plan," "project," "potential," "seek," "may," "will," "expect," "believe," "anticipate," "intend," "could," "estimate" or "continue" are intended to identify forward-looking statements. Readers are cautioned that certain important factors may affect the Company's actual results and could cause such results to differ materially from any forward-looking statements that may be made in this news release. Factors that may affect the Company's results include, but are not limited to, regulatory approvals, product demand, market acceptance, impact of competitive products and prices, product development, commercialization or technological difficulties, the success or failure of negotiations and trade, legal, social and economic risks, and the risks associated with the adequacy of existing cash resources. Additional factors that could cause or contribute to differences between the Company's actual results and forward-looking statements include, but are not limited to, those risks discussed in the Company's filings with the U.S. Securities and Exchange Commission. Readers are cautioned that actual results (including, without limitation, the results of the Company's commercial and regulatory plans for Dario as described herein) may differ significantly from those set forth in the forward-looking statements. The Company undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable law.
Dario™ and the Dario™ logo are trademarks owned by LabStyle Innovation Ltd.
© 2013 LabStyle Innovations Corp. All rights reserved.
©2012 PR Newswire. All Rights Reserved.